Close
10/02/2016
New mechanism of anti-tumour action for the new drug developped at the UAB
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park, Barcelona Synchrotron Park partner), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.

The study, which has been published in the prestigious journal Clinical Cancer Research, was coordinated by Dr José Miguel Lizcano from the UAB Institute of Neurosciences and Department of Biochemistry and Molecular Biology.

Through the newly identified mechanism, ABTL0812 attacks tumour cells without affecting healthy cells, causing their death by autophagy without activating apoptosis (programmed cell death). It is the first anti-tumour drug to act in this way.

ABTL0812 has recently undergone Clinical Phase I trials in patients with advanced cancer, showing efficacy in several patients (long term stabilization) as well as low toxicity and high tolerability. Clinical Phase II trials are due to start soon in patients with endometrial cancer and lung squamous cell carcinoma.

More news

03/08/2016 Pier 01, the new Barcelona technology hub 28/07/2016 Zero 2 Infinity sends satellites into space 22/07/2016 Latest SENER News From Space and the Sun 16/07/2016 ​Les Dames de Cerdanyola 08/07/2016 The ALBA Synchrotron reveals the inside of hepatitis C-infected cells 30/06/2016 The Bioinformatics Barcelona Initiative
23 24 25 26 27 28 29 30 31 32 33